599315 Disclosed is the use of a polyclonal, milk-derived, anti-TNF antibody in the manufacture of a medicament to treat inflammatory bowel disease wherein the peak level of anti-TNF antibody in the patient’s serum is less than about 1 microgram/ml after administration of the medicament.